Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment
Natalie J Hannan, Fiona C Brownfoot, Ping Cannon, Minh Deo, Sally Beard, Tuong V Nguyen, Kirsten R Palmer, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
SCIENTIFIC REPORTS | NATURE PUBLISHING GROUP | Published : 2017
Preeclampsia is a disease of pregnancy associated with placental oxidative stress, inflammation and elevated release of anti-angiogenic factors sFlt-1 and soluble endoglin. These placental factors cause generalized maternal endothelial dysfunction. There are no treatments to halt disease progression; delivery is the only cure. Resveratrol modulates pathways involved in inflammation and oxidative stress and may offer a potential therapeutic for preeclampsia. Resveratrol reduced sFlt-1, sFlt-1 e15a and soluble endoglin secretion from primary trophoblasts and HUVECs and reduced mRNA expression of pro-inflammatory molecules NFκB, IL-6 and IL-1β in trophoblasts. IL-6, IL-1β and TNFα secretion wer..View full abstract
Related Projects (2)
Awarded by NHMRC
We would like to thank the research midwives, Gabrielle Pell, Genevieve Christophers, Rachel Murdoch and Debra Jinks, and patients at Mercy Hospital for Women for participating in this research. The NHMRC provided salary support (#1050765 to ST #1062418 to T.K.L.). N.J.H. salary was supported by a University of Melbourne CR Roper Fellowship. The funders had no role in study design, data collection, analysis or decision to publish.